Toggle light / dark theme

I am not surprised at all by this finding given the other issues with pollution such as cancer from carcinogens, asthma, sinus infections, etc.


Air pollution is a known culprit in lung and heart disease. Fine particulate matter, tiny particles, 1/30th the width of a human hair, are released into the air by power plants, factories, cars and trucks. These fine particles somehow invade the body’s defenses and do the most damage. Air quality is worst in urban areas with increased traffic. New research points out that air pollution negatively affects brain and cognitive development in young children and teenagers.

Moreover, Jennifer Weuve, an assistant professor of internal medicine at Rush Medical College, found that older women who had been exposed to high levels of the pollution experienced greater cognitive decline compared with other women their age (Archives of Internal Medicine, 2012). Other studies cite black carbon in the form of soot as a cause of cognitive decline in an aging population for both men and women. Simply put: Dirty air messes up the brain.

In a new study conducted by a research team at Umeå University in Sweden, the correlation between exposure to air pollution in residential areas and children’ and adolescents’ psychiatric health was studied. The results show that air pollution increased the need for prescribed psychiatric medication for a mental illness. “The results can mean that a decreased concentration of air pollution, first and foremost traffic-related air pollution, may reduce psychiatric disorders in children and adolescents,” says lead researcher Anna Oudin, the Unit for Occupational and Environmental Medicine at the Department of Public Health and Clinical Medicine.

Read more

Nice.


In a pair of firsts, researchers at Case Western Reserve University and Massachusetts Institute of Technology have shown that the drug candidate phenanthriplatin can be more effective than an approved drug in vivo, and that a plant-virus-based carrier successfully delivers a drug in vivo.

Triple-negative breast cancer tumors of mice treated with the phenanthriplatin –carrying nanoparticles were four times smaller than those treated either with cisplatin, a common and related chemotherapy drug, or free phenanthriplatin injected intravenously into circulation.

The scientists believe the work, reported in the journal ACS Nano, is a promising step toward clinical trials.

Read more

Very nice; researchers have now discovered a method for viewing deep brain imaging through using NIR light at wavelengths of 1600–1870nm Very big deal especially for patients with things like Giloblastoma Multiforme (GBM), and other neuro disorders and diseases.

I remember when my two aunts suffered from GBM, and many doctors could not get iimaging view in some areas of my aunts brains which would have been beneficial in understanding how ingrain the GBM was in their brain cells. So, hopefully this finding will help others in getting better answers to diseases like GBM and in turn better treatment as well developed.


Near-IR light at wavelengths of 1600–1870nm offers the best transmittance for deep brain imaging.

One of the major goals in neuroscience is to image the structure of the brain at cellular resolution. However, achieving deep brain tissue imaging has posed a significant challenge because of technical limitations in accessing wavelengths beyond 950nm. Recently, the availability of new technologies, such as suitable near-infrared (NIR) detectors and femtosecond laser sources, offer great potential for deep brain imaging. Now, we have discovered a ‘ golden window’ that uses NIR light at wavelengths of 1600–1870nm, which offers the optimal transmittance for deep brain imaging. 1, 2.

Read more

Robotic exoskeletons, long a staple of sci-fi novels, comic books, and movies, are now part of the real world—and they’ve mostly followed the sci-fi model. That is, exoskeletons are wearable robots. All metal, all the time. But metal suits are heavy and power hungry, and the human body isn’t metal. If you actually plan to use an exoskeleton for an extended period of time, this can be a bit of a design flaw.

That’s where a new exosuit developed by SRI International is looking to flip the script. Instead of working to build exoskeletons—which are rigid like their namesake—SRI is using soft robotics to make lightweight, wearable “exomuscles” and “exotendons.”

Instead of a human-shaped heavy metal frame, SRI’s exosuit is soft, pliable, and intelligent. The suit learns and adapts to its wearer’s movements to give them a boost when needed. It’s quick to put on and relatively energy efficient.

Read more

I have fond memories of both of my grandfathers as a boy growing up in the American Southwest. My mother’s father was a master gardener, able to grow plants in an arid environment that should have thrived only in tropical rainforests. Botanists from the Department of Biology at the local university surveyed his garden, and promptly asked him to help with problems they were experiencing in their greenhouses. There were large fruit trees scattered throughout his backyard perfect for climbing and eating apples, peaches, or cherries fresh off the branch. The foliage of these trees was dense, making it possible to hide and pounce down on unsuspecting younger brothers or cousins wandering too near the danger zone. Not saying I ever did such a thing, just saying it was possible. You know?

Every Friday night we ate dinner at my mother’s parents’ house. I poignantly remember an after dinner ritual. My grandfather would retire to his recliner, toothpick in his mouth, and instruct one of his grandchildren to turn on the bulky multicomponent console color television with built in radio, turntable, and speakers. It was time to watch Friday night boxing. There was no remote control, we kids were the channel changers and volume knob manipulators. My grandfather was usually not an emotional man, but he would become quite animated and occasionally agitated watching the fight, particularly if there was a boxer he favored in the match. The grandchildren enjoyed watching him more than we did the pugilists on the flickering television screen.

My father’s father, on the other hand, was a wrestling fan. By wrestling, I mean the wrestling seen on Saturday afternoon television featuring men in tight shorts, outlandish costumes, some wearing hoods or masks over their heads, entering the ring wearing colorful capes to either wild applause or catcalls and hisses, bouncing off the ropes to clothesline their onrushing opponent, and jumping from the turnbuckles to land on their hapless opponent laid out on the mat below. Even to a boy it was obvious bad theater and fraud, but I enjoyed watching my grandfather yelling at the television, berating the bad guys and the referees during these spectacles. He knew the name of every hero and villain, and he would hurl epitaphs at the masked men in tight wrestling suites while openly cheering for those he admired. He particularly loved the chaos of tag team matches, guaranteed to degenerate into a free-for-all with all the combatants in the ring, throwing chairs, and occasionally even body slamming the referee to the canvas. I still remember some of the names and can mentally visualize the antics; Gene Kiniski, The Sheik, Ray Mendoza, Dory Funk Jr., Terry Funk, Mad Dog Vachon, Hard Boiled Haggarty, Raul Reyes, Killer Kowalski, and Johnny Valentine. As I grew older I mistakenly pointed out these matches were all rehearsed and the outcomes were scripted; this wasn’t real sport. He fixed me with a glare, informed me I was getting, “a little too big for my britches”, and asked me if I thought 250 lb. men climbing to the top of the ropes to hurl themselves on their foe below, or the prostrate , seemingly stunned wrestler on the mat absorbing the flying blow delivered from above should be considered as anything less than athletic.

Good point. I wouldn’t want to do it.

Cancer patients and caregivers grapple with malignant disease every day. Surgical oncology is an unusual, but not unique, sub-specialty area in surgical care. Many surgeons will enter the lives of their patients for an acute illness or event, perform the indicated operation to improve their condition, care for them in the hospital, and then see them for one or two post-operative visits in the office before discharging them on to the rest of their lives. Some surgical sub-specialties, including surgical oncology, follow their patients longitudinally. All of the oncology-related specialties follow their patients for years, if not for the lifetime of our patients after a diagnosis of cancer. We are watching for the success of our treatment, evidence of any recurrent or new metastatic disease, and treating any symptoms or problems related to the therapies we deliver. We get a chance to know our patients and their families, and to watch how they respond to a diagnosis of cancer and to living with the ever-present specter of possible return of malignant disease.

I admire the pluck and defiance of patients who have a “never give up” attitude. One of those patients is on my mind today. When I walked into an examination room to meet him, he sprang to his feet, grasped my hand and shook it vigorously, smiled a dazzling white smile, and then gave me a bear hug. Effusive. His first words, “Doc, you’re going to help me beat this thing!” At this point he was still shaking my hand, his grip getting tighter, so I politely asked him to release my hand lest I be unable to perform an operation on him because of damaged digits. He laughed and immediately cut me loose, allowing circulation to return to my fingers. We sat down to talk. I was not surprised this gentleman had an impressive grip. He was in his late 40s and built like a football running back or rugby player. I actually asked him if he had been a football player. He feigned disgust and exasperation and said, “No, I’m a real athlete. I am a wrestler.” As I explored his history it turned out he had been a collegiate wrestler of significant accomplishment and repute. After completing his collegiate career, he founded a successful business and spent his time raising his family, expanding his business acumen, and refereeing high school and college wrestling matches around his home state.

I was seeing this man for a diagnosis of colorectal cancer liver metastasis. Eight months prior to our initial meeting, he noticed some blood in his bowel movements and made an appointment with his primary care physician. His doctor noted that he did have blood on a rectal exam and that he was slightly anemic on blood tests. He had never before had a colonoscopy and there was no family history of colon cancer. A gastroenterologist was consulted and a colonoscopy revealed a colon cancer. The patient underwent an operation in his hometown to remove the malignant colon tumor. The gross and microscopic review of the surgical resection specimen by a pathologist discovered cancer in several lymph nodes near the primary tumor, and a biopsy of a liver tumor performed by the surgeon confirmed liver metastasis in the right lobe of his liver. Stage IV disease, signifying blood-borne spread, successful implantation, and growth of malignant cells from the colon cancer to another organ, his liver.

The patient recovered from his colon operation at a meteoric pace (his hometown surgeon’s description when I spoke to him), and then received six months of systemic intravenous chemotherapy. He was referred to me to address the sole clinically evident site of malignant disease, a tumor in the right lobe of his liver. I use the statement “clinically evident” purposefully, on our state-of-the-art computerized tomography (CT) scans the radiologists and I did not detect any suspicious tumors or “lesions” in his lungs, lymph nodes, or peritoneal cavity. Just a solitary liver metastasis smack dab in the middle of the right lobe. An almost Pavlovian circumstance for a hepatobiliary surgical oncologist who loves to attack and remove liver malignancies in this remarkably fit, healthy young man.

This gentleman was one of the most energetic, positive attitude, “let’s get this done” people I have met in any aspect of my life. We talked for about half an hour during our first visit, and I performed a physical examination. I reviewed the CT scans we performed and the pathology information he brought with him. He had a 5 cm liver tumor which originally was almost 8 cm in diameter. The tumor volume reduction indicted a positive response to chemotherapy. In oncology, numerous studies have indicated patients showing shrinkage of their tumors with chemotherapy tend to have a longer survival time after surgical and other anti-cancer therapies. It’s all statistics and probabilities; the bottom line is we can never know what’s going to happen specifically to one given patient. This patient told me he was ready for me to operate and “get this devil out of me” as quickly as possible.

The next week I performed an exploratory laparotomy. Surgeons are multi-sensory creatures. We like to visually inspect the area of the operation, but we also like to feel. I palpated the lymph nodes near the blood vessels heading into his liver. Several of them felt hard like small stones despite not being enlarged. I removed all of these regional lymph nodes adjacent to the liver and then completed a routine right hepatectomy. Upon checking the remainder of the belly cavity visually and tactilely, there was no evidence of tumor to be found at any other site.

My patient was up walking laps in the hallways of the surgical unit the night of his operation. Several nurses told me they were exhausted just watching him. He was indefatigable. He consistently had a huge smile on his face and greeted everyone with a bone-crushing handshake. He left the hospital only four days after his operation. As he stated, “All systems are working, I’m outta here.”

See ya!

I saw him in clinic the following week and we reviewed the results from surgery. I explained to him the pathologist found not only the single liver tumor we knew was present, but also three additional 2–3 mm tumors were detected near the large tumor. None of these tumors was close to the liver transection line, we had achieved a tumor margin-negative operation. Furthermore, three of the twelve lymph nodes removed from around the blood vessels supplying his liver contained metastatic colorectal cancer. He was nonplussed, and asked if it was still possible to be cured. The question I get every week. I explained the finding of the small tumors in the liver combined with lymph node metastases meant there was a higher probability he could have microscopic cancer cells hiding elsewhere in his body. In other words, his chance for long-term cancer free survival was significantly reduced, but was not zero. I finished with the assurance I planned to follow him closely and watch for any recurrence. That earned me a grand smile, more damage to my right hand, and an exhalation-inducing embrace. He returned home and spoke to his medical oncologist. They decided to proceed with another six months of a different chemotherapy regimen. At the end of the second six months of cytotoxic drugs, he returned to see me in clinic. All of our blood tests and CT scans on him showed no problem, no clinically evident cancer.

I wasn’t sure if my right hand or chest was going to remain intact thanks to this patient.

The good results and good news were short lived. Six months later, a blood test we measure in patients with colorectal cancer called CEA, an abbreviation for carcinoembryonic antigen, was elevated in him. When I saw his lab results, I immediately scrolled through his CT scans, and then quietly cursed at the computer screen. He had four new tumors in the hypertrophied left lobe of his liver along with a dozen or more small lung metastases scattered throughout both lungs. I walked into an examination room to tell him the news. He knew from my face I was about to drop a bomb on him. Before I could say anything, he stood up, hugged me, and to my amazement said, ”We’ll beat this thing!” I reassured him we were in the fight together and I then went over all of his results. He sat quietly nodding, occasionally asking for clarification, and finally asked, “Okay, what’s our next move?” I spoke with my colleagues in medical oncology and we determined a new sequence of drugs to treat him for this rapid recurrence.

At a visit with me three months later, he launched the question patients often ask, he wanted to know how long he would live. He was a motivated, insightful, intelligent individual and as we sat together in a clinic room, he rifled through copies of scientific papers describing chemotherapy and novel treatments for stage IV colorectal cancer. He noted from his reading the median survival with the chemotherapy drugs he was receiving ranged from 18–24 months. I replied those perceptions and statistics were correct, but there was no way to predict if he would live less or more time than the average. He laughed, tossed the research papers on the floor, and said, “These don’t describe me!”

After six months of additional chemotherapy, this gentleman’s lung metastases had completely disappeared on CT scans of the chest, and the liver metastases appeared to be calcified scar tissue. His CEA blood test had returned to a normal value. After considering his situation and excellent anti-tumor response in a tumor board meeting, my colleagues and I determined we would stop chemotherapy and follow him. This we did with blood tests, CT scans, and physical examinations every three months for another year. At the one year off chemotherapy mark, his CEA value was again elevated and CT scans revealed recurrence in the liver, lungs, and peritoneal cavity. Grimly, I walked into the examination room to have a heartrending discussion. I reviewed the test results as his wife quietly wept, and before addressing me, he turned to her, gave her a hug, and told her he would be all right. He pivoted to me and flashed a dazzling smile saying, “Remember, we are in this together.”

Yes we are. Based on probabilities, patterns, and the rapid recurrence of his cancer in multiple sites, this man would not have been predicted to survive more than 2 or 3 years after his initial cancer diagnosis. I mentioned previously he was on my mind because I received a note from his brother recently informing me he had finally lost his battle and had passed away. It was almost 8 years from the time of his original cancer diagnosis. Throughout all of those years I saw him every 3 months and arranged for him to see numerous specialists and medical oncologists administering a variety of new clinical trials for colorectal cancer. His medical oncologist at home is very active in treating patients with established and new regimens for gastrointestinal malignancies. When we spoke on the phone about our mutual patient, it was always with a note of admiration for his courage and formidible spirit.

I grew up watching boxers and faux wrestlers (performance athletes?) with my grandfathers. Several of the wrestlers we watched on Saturday afternoon television had been college wrestlers, some even competing in the Olympics. They were indeed athletes. Not great actors, but athletes, nonetheless. Perhaps the ability to work hard, to strive, to endure pain and discomfort and defeat is what led my patient, the wrestler, to survive as long as he did. I have seen similar powerful and courageous efforts from patients of all ages and backgrounds. I am reminded of a verse of the lyrics from one of my favorite songs from childhood, “The Boxer”, performed by Paul Simon and Art Garfunkel.

In the clearing stands a boxer,

and a fighter by his trade

And he carries the reminders

of every glove that laid him down or cut him

till he cried out, in his anger and his shame,

“ I am leaving, I am leaving”,

but the fighter still remains.

Warrior terminology abounds in the cancer lexicon. “The War on Cancer.” “She lost her battle with cancer.” “I am fighting cancer.” ‘We are going to attack your cancer with every weapon in our arsenal.” “He refuses to surrender and will keep battling.” “She is soldiering on through this fight with cancer.” “I am going to beat and defeat this cancer.” “It was a courageous fight.” “We have your cancer on the ropes.”

Patients diagnosed with cancer and treated with our multidisciplinary approaches are knocked down physically and emotionally, but they pick themselves up off the canvas and struggle on. They carry the reminders of the acute and chronic side effects from cytotoxic chemotherapy, the radiation-induced skin and functional organ changes, and the surgical scars, complications, and impairments imposed by the blades of surgical oncologists like me. Though sometimes they want to, they don’t leave. They remain. They maintain. I respect the effort, the invincible spirit, and the patients who don’t give a damn about the odds or probabilities; they are going out swinging. We are tag team partners in Oncology, entering the ring to attack a patient’s cancer with every move and method we know. Hell, I’ll even throw a few chairs if it will help.

Indomitable. The wrestler. I honor you.

What will we do when money has no meaning? And if everyone gets life extension what will today’s mega rich think and/or do about it?


May you live in interesting times – A curse, origin unknown

One of the ‘curses’ usually attributed to ancient China, but frequently thrown around in today’s society is ‘May you live in interesting times’, suggesting that living in turbulent times, no matter the cause, is somehow a bad thing.

True or not, there is no denying one thing – every individual fragment of time was interesting in its own right, and I’ll be free to say that life has never been as interesting as it is today. Just look at what humans did in the last 40 years – first we got computers, then the internet, mobile phones, smartphones, high-speed internet, high-speed internet on smartphones, social media, virtual reality, augmented reality, drones, exoskeletons, prosthetic mind-controlled limbs… all of these things happened in less than a single lifetime.

Read more

Promising.


Early trial data shows a drug developed using artificial intelligence can slow the growth of cancer in clinical trials.

The data, presented at the American Society of Clinical Oncology conference, showed some tumours shrank by around a quarter.

The compound will now be taken into more advanced trials.

Read more

Medical/ Biocomputing will only continue to grow and advance as a result of the demand for more improved experiences by consumers and business in communications and entertainment, food, home life, travel, business, etc.

Today, we have seen early opportunities and benefits with 3D printing, BMI, early stage Gene/ Cell circuitry and computing. In the future, we will see these technologies more and more replaced by even more advance Biocomputing and gene circuitry technology that will ultimately transform the human experiences and quality of life that many like to call Singularity.


Printing technology has come a long way from screechy dot-matrix printers to 3D printers which can print real life objects from metals, plastics, chemicals and concrete. While, at first, 3D printers were being used to create just basic shapes with different materials, more recently, they have been used to create advanced electronics, bio-medical devices and even houses.

Aircraft manufacturer Airbus recently showcased the world’s first 3D-printed mini aircraft, Thor, at the International Aerospace Exhibition and Air Show in Berlin. Although Airbus and its competitor have been using 3D-printed parts for their bigger assemblies, recent attempt shows that aviation may be ready for a new future with much lighter and cheaper planes given 3D printing not only cuts down the costs with less wastage, it also makes the plane lighter, thereby making them faster and more fuel efficient. But planes and toys is not what 3D printing might be restricted to; though in the elementary stage at the moment, the technology is being used for creating complex electronics like phones and wearables and may be able to reduce costs for manufacturers like Samsung and Apple.

One of the most important uses for the technology comes in the field of medical sciences. While pharma companies have been working on producing medicines from 3D printers, with one winning approval from the US’s Food and Drug Administration earlier this year, the technology is also being used to create bones, cartilages and customisable prosthetic limbs. But the real test for the technology lies in bioprinting—creating living cells via a 3D printer. Doctors have been using 3D printed organs to practice on, but scientists at research institutes have been experimenting with printing stem cells, skin tissue, organs and DNA. Though this is still decades from being a reality, printing of regenerative tissues can help cure heart ailments. 3D printing is also helping in construction, with a printer being used to create the first office space in Dubai using concrete blocks. The city aims that 25% of its buildings will be 3D printed by 2030.

Read more

SRI is developing wearable “exosuits” that can augment the musculoskeletal system for performance and strength enhancement and assistance to overcome or prevent damage from injury or disease. SRI’s exosuit differs from exoskeletons by using new muscle-like actuation, comfortable and soft skin attachment, and electronically releasable spring elements to minimize mass, bulk, and noise as well as eliminate constraints on natural joint motions. As part of DARPA’s Warrior Web Program, the technology is being applied to prevent and reduce musculoskeletal injuries caused by dynamic events typically found in the warfighter’s environment. They are exploring other military applications and beginning to use the technologies to assist individuals with musculoskeletal diseases.

The wearable exosuit, Superflex, uses motion sensors, accelerometers and gyroscopes to read the speed and angles of the owner’s legs and adjust its movements accordingly.

On April 21, 2016 – SRI International announced the launch of Superflex, Inc., its newest spin-off venture. Superflex will develop cutting-edge wearable robotics to enhance the human musculoskeletal system for a wide range of applications.

Read more

There are various animals that can live for centuries or millenia.

Genetic engineering technology is rapidly improving and genome wide genetic engineering could become a reality within 10–20 years. It could be possible to replicate in humans the longevity genes and cancer immunity in certain animals.

The longest lived mammal is the bowhead whales. Some confirmed sources estimate bowhead whales to have lived at least to 211 years of age.

Read more